NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries (EXPEDE)
Primary Purpose
Corneal Persistent Epithelial Defect
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Nexagon® (lufepirsen) High Dose Concentration
Nexagon® (lufepirsen) Low Dose Concentration
Vehicle
Open-label Nexagon® (lufepirsen)
Sponsored by

About this trial
This is an interventional treatment trial for Corneal Persistent Epithelial Defect
Eligibility Criteria
Inclusion Criteria:
- Male and female of any age.
- The presence of a non-infected, corneal persistent epithelial defect (PED) which has resulted from a severe chemical and/or thermal (burn) injury to one or both eyes.
- The PED is non-responsive to current standard of care for at least 14 days from injury.
- The PED measures at least 2 mm along the largest diameter at Day 1 of the Treatment Period.
- Providing written informed consent and ability to comply with the visit and dosing schedule.
Exclusion Criteria:
- Subjects who will be unlikely to tolerate the wearing of a Bandage Contact Lens.
- Have active ocular infection.
- Subjects with corneal perforation or impending corneal perforation.
- Subjects with any other past or present ophthalmic disease or medical condition that, in the Investigator's opinion, may affect the safety of the subject or the outcome of the study.
- Subjects receiving systemic corticosteroids (equivalent to GREATER THAN 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents unless the dose has remained unchanged for 30 days and will remain unchanged during the study.
- Subjects being treated with systemic corticosteroids (equivalent to >10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents unless the dose has remained unchanged for 30 days prior to Day 1.
- Subjects with severe lid abnormalities or ocular conditions that contribute to the persistence of the epithelial defect.
- Female subjects of childbearing potential who are pregnant, nursing, planning a pregnancy or not using an adequate and medically acceptable form of birth control.
- Subjects who have participated in an interventional clinical trial within 30 days prior to Day 1.
Sites / Locations
- Jules Stein Eye InstituteRecruiting
- Colorado Eye ConsultantsRecruiting
- Cincinnati Eye InstituteRecruiting
- University of MinnesotaRecruiting
- Mercy Eye CareRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Nexagon® (lufepirsen) High Dose Concentration
Nexagon® (lufepirsen) Low Dose Concentration
Vehicle
Arm Description
Outcomes
Primary Outcome Measures
The proportion of subjects achieving corneal epithelial recovery, as assessed by slit lamp examination.
Corneal epithelial recovery, defined as corneal reepithelialization and maintenance of a durable epithelium for at least 28 days, will be assessed by slit lamp examination.
Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v 5.0
Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v 5.0.
Secondary Outcome Measures
Time to corneal epithelial recovery, as assessed by slit lamp examination.
The time (number of days) from randomization to the time of initial re-epithelialization for a cornea that remains re-epithelialized and durable for at least 28 days will be recorded following confirmation by slit lamp examination.
Improvement from baseline of visual acuity measured by the Snellen scale.
Improvement of visual acuity on the Snellen scale from baseline until study exit will be measured.
The number of NEXAGON treatment doses required to achieve recovery of the corneal epithelium will be assessed.
The number of NEXAGON dose applications required to achieve corneal epithelial recovery will be recorded. Corneal epithelial recovery is defined as corneal reepithelialization and maintenance of a durable epithelium for at least 28 days and will be confirmed by slit lamp examination.
Full Information
NCT ID
NCT04081103
First Posted
August 29, 2019
Last Updated
August 25, 2022
Sponsor
Amber Ophthalmics, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT04081103
Brief Title
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries
Acronym
EXPEDE
Official Title
A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled Study to Assess the Efficacy and Safety of Nexagon® (NEXAGON) Applied Topically in Subjects With Corneal Persistent Epithelial Defects Resulting From Severe Ocular Chemical and/or Thermal Injuries
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2020 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Amber Ophthalmics, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care for at least 14 days. It will assess the efficacy and safety of Nexagon® (lufepirsen) plus standard of care versus NEXAGON-vehicle (placebo) plus standard of care. The recovery of the corneal epithelium will be the primary outcome measure, defined as a cornea that re-epithelializes by Day 28 of treatment and remains re-epithelialized for at least a further 28 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Corneal Persistent Epithelial Defect
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
108 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Nexagon® (lufepirsen) High Dose Concentration
Arm Type
Experimental
Arm Title
Nexagon® (lufepirsen) Low Dose Concentration
Arm Type
Experimental
Arm Title
Vehicle
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Nexagon® (lufepirsen) High Dose Concentration
Intervention Description
Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
Intervention Type
Drug
Intervention Name(s)
Nexagon® (lufepirsen) Low Dose Concentration
Intervention Description
Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
Intervention Type
Drug
Intervention Name(s)
Vehicle
Other Intervention Name(s)
Placebo
Intervention Description
Vehicle is administered topically in the affected eye three (3) times over 28 days.
Intervention Type
Drug
Intervention Name(s)
Open-label Nexagon® (lufepirsen)
Intervention Description
Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
Primary Outcome Measure Information:
Title
The proportion of subjects achieving corneal epithelial recovery, as assessed by slit lamp examination.
Description
Corneal epithelial recovery, defined as corneal reepithelialization and maintenance of a durable epithelium for at least 28 days, will be assessed by slit lamp examination.
Time Frame
Up to 56 days.
Title
Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v 5.0
Description
Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v 5.0.
Time Frame
Up to 30 days after last application of intervention
Secondary Outcome Measure Information:
Title
Time to corneal epithelial recovery, as assessed by slit lamp examination.
Description
The time (number of days) from randomization to the time of initial re-epithelialization for a cornea that remains re-epithelialized and durable for at least 28 days will be recorded following confirmation by slit lamp examination.
Time Frame
Within 28 days
Title
Improvement from baseline of visual acuity measured by the Snellen scale.
Description
Improvement of visual acuity on the Snellen scale from baseline until study exit will be measured.
Time Frame
Up to 56 days
Title
The number of NEXAGON treatment doses required to achieve recovery of the corneal epithelium will be assessed.
Description
The number of NEXAGON dose applications required to achieve corneal epithelial recovery will be recorded. Corneal epithelial recovery is defined as corneal reepithelialization and maintenance of a durable epithelium for at least 28 days and will be confirmed by slit lamp examination.
Time Frame
Within 56 days
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female of any age.
The presence of a non-infected, corneal persistent epithelial defect (PED) which has resulted from a severe chemical and/or thermal (burn) injury to one or both eyes.
The PED is non-responsive to current standard of care for at least 14 days from injury.
The PED measures at least 2 mm along the largest diameter at Day 1 of the Treatment Period.
Providing written informed consent and ability to comply with the visit and dosing schedule.
Exclusion Criteria:
Subjects who will be unlikely to tolerate the wearing of a Bandage Contact Lens.
Have active ocular infection.
Subjects with corneal perforation or impending corneal perforation.
Subjects with any other past or present ophthalmic disease or medical condition that, in the Investigator's opinion, may affect the safety of the subject or the outcome of the study.
Subjects receiving systemic corticosteroids (equivalent to GREATER THAN 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents unless the dose has remained unchanged for 30 days and will remain unchanged during the study.
Subjects being treated with systemic corticosteroids (equivalent to >10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents unless the dose has remained unchanged for 30 days prior to Day 1.
Subjects with severe lid abnormalities or ocular conditions that contribute to the persistence of the epithelial defect.
Female subjects of childbearing potential who are pregnant, nursing, planning a pregnancy or not using an adequate and medically acceptable form of birth control.
Subjects who have participated in an interventional clinical trial within 30 days prior to Day 1.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
President and CSO, PharmD
Phone
(858) 663-1500
Email
clinical@amberophthalmics.com
Facility Information:
Facility Name
Jules Stein Eye Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ellen Pascual
Phone
310-794-5592
Email
pascual@jsei.ucla.edu
First Name & Middle Initial & Last Name & Degree
Anthony Aldave, MD
Facility Name
Colorado Eye Consultants
City
Littleton
State/Province
Colorado
ZIP/Postal Code
80120
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shivam Patel
Phone
303-730-0404
Email
spatel@corneaonline.com
First Name & Middle Initial & Last Name & Degree
S. Lance Forstot, MD
Facility Name
Cincinnati Eye Institute
City
Edgewood
State/Province
Kentucky
ZIP/Postal Code
41017
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katie Hogeback
Phone
859-331-9000
Ext
4517
Email
khogeback@cvphealth.com
First Name & Middle Initial & Last Name & Degree
Edward Holland, MD
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joshua Hou, MD
Phone
612-626-1442
Email
jhhou@umn.edu
First Name & Middle Initial & Last Name & Degree
Joshua Hou, MD
Facility Name
Mercy Eye Care
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65804
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Connelly
Phone
417-820-7493
Email
diana.connelly@mercy.net
First Name & Middle Initial & Last Name & Degree
Zachary Seagrave, MD
12. IPD Sharing Statement
Learn more about this trial
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries
We'll reach out to this number within 24 hrs